Insider txns (12m)
0
Stock / equity
AKUS Akouos, Inc.
- Company
- Akouos, Inc.
- Security
- Equity
- Insiders on record
- 1
- Latest trade on record
- June 30, 2020
AKUS (Akouos, Inc.) has 0 disclosed insider transactions from 0 insiders in the last 12 months (0 open-market buys, 0 sales, about $0 at reported prices) and 0 congressional trades from 0 members of Congress. The most recent disclosure was filed July 2, 2020.
Open-market buys / sales
0 / 0
Congress trades (12m)
0
Distinct filers (12m)
0
Share price
Price and chart by TradingView for Akouos, Inc.. US share prices here are delayed, not real-time. The trade records on this page come from government filings, not from this chart.
Insiders trading AKUS
Everyone who filed a Form 4 for this ticker, by number of rows on record. "Bought" and "sold" count open-market purchases (code P) and sales only; awards, option exercises and shares withheld for tax are in the row count but not in those two columns.
| Insider | Role | Rows | Bought | Sold | Value bought | Value sold | Latest |
|---|---|---|---|---|---|---|---|
| Novartis Bioventures Ltd | Insider | 5 | 1 | 0 | $2.1M | — | June 30, 2020 |
What kind of transactions these are 2 Form 4 codes
| Code | Meaning | Rows | Shares | Value at reported prices |
|---|---|---|---|---|
| C | Conversion of a derivative | 4 | 2,112,516 | — |
| P | Open-market purchase | 1 | 125,000 | $2.1M |
What each code means: Form 4 transaction codes.
Insider transactions
| Filer | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Bioventures Ltd | Exchange C | June 30, 2020 | July 2, 2020 | 2d | 199,996 | — | — | indirectderivative | Form 4 ↗ | |
| Novartis Bioventures Ltd | Exchange C | June 30, 2020 | July 2, 2020 | 2d | 856,262 | — | — | indirectderivative | Form 4 ↗ | |
| Novartis Bioventures Ltd | Buy P | June 30, 2020 | July 2, 2020 | 2d | 125,000 | $17 | $2.1M | indirect | Form 4 ↗ | |
| Novartis Bioventures Ltd | Exchange C | June 30, 2020 | July 2, 2020 | 2d | 199,996 | — | — | indirect | Form 4 ↗ | |
| Novartis Bioventures Ltd | Exchange C | June 30, 2020 | July 2, 2020 | 2d | 856,262 | — | — | indirect | Form 4 ↗ |
Congressional trades
No member of Congress has disclosed a trade in this ticker in the filings we have parsed.
Related stocks
Tickers traded by the same people who traded AKUS, by number of filers in common. It shows overlap in public filings and nothing else.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 5 | July 2, 2020 | July 2, 2020 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insider rows are Form 4 filings for this issuer from SEC EDGAR; congressional rows are periodic transaction reports parsed from the House Clerk and the Senate eFD. Values use the reported price for Form 4 and the disclosed range for Congress. See methodology and corrections.
Not investment advice. Disclosures are shown as filed and may lag the trade or be amended. No recommendation is made or implied.